鼻咽癌病人血清抗EB病毒特异性DNA多聚酶活性的研究

A Study on the Anti-EBV Specific DNA Polymerase Activities of Nasoparyngeal Carcinoma (NPC) Patients' Sera

本文报道了111例鼻咽癌病人,30例其他癌瘤病人和93例正常人血清抗EB病毒DNA多聚酶抗体的水平。将血清抗酶率≥30％看作是该抗体阳性,血清阳性率分别是:鼻咽癌病人85.6％,其他癌瘤病人6.7％,正常人6.5％,鼻咽癌病人血清抗酶率与病人的病理、分期、病型、年龄及性别无关。检测该抗体可望发展成一种鼻咽癌早期诊断的辅助方法。 本文还探讨了影响检测结果的几个因素,认为用抗酶率表示抗体水平比用抗酶单位更好。

The levels of antibody to EBV specific DNA polymerase (EBV-DP) in sera of H] nasopharyngeal carcinoma (NPC) patients, 30 other cancer patients and 93 normal individuals were determined. If over 30% of the enzyme activity neutralized by serum was regarded as positive, the positive rate was 85.6% in-NPC patients, 6.7% in other cancer patients and 6.5% in normal individuals respectively. The level of the antibody in sera of NPC patients was independent of the pathomorphological classification, clinical stage, clincal type, age and sex of patients. The data suggest that the detection of the level of the antibody against EBV-DP may be developed as an adjuvant method for the early diagnosis of NPC. Several factors affecting the results of detection of the antibody to EBV-DP in sera were also studied, It is suitable to use the anti-enzyme rate (%) to measure the level of antibody rather than the anti-enzyme unit (U/ml serum).